Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model

[1]  I. Abraham,et al.  Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials , 2016, Cancer medicine.

[2]  C. Slingluff,et al.  Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. , 2016, Immunotherapy.

[3]  Emily B. Ehlerding,et al.  Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab , 2017, The Journal of Nuclear Medicine.

[4]  S. Gambhir,et al.  Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. , 2015, Bioconjugate chemistry.

[5]  S. Gambhir,et al.  Radiation Dosimetry Study of [89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography , 2015, Molecular Imaging and Biology.

[6]  David C. Smith,et al.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Roth,et al.  Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model , 2015, Journal of Immunotherapy for Cancer.

[8]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[9]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[10]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[11]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[12]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Mamalis,et al.  Targeting the PD-1 pathway: a promising future for the treatment of melanoma , 2014, Archives of Dermatological Research.

[14]  Xiumin Wang,et al.  PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients , 2014, Cancer Immunology, Immunotherapy.

[15]  V. Sondak,et al.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma , 2013, Nature Reviews Clinical Oncology.

[16]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[17]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[18]  Asher Mullard.  New checkpoint inhibitors ride the immunotherapy tsunami , 2013, Nature Reviews Drug Discovery.

[19]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[20]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[21]  S. Gambhir,et al.  Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. , 2012, Bioconjugate chemistry.

[22]  R. McIntyre,et al.  Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[23]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[24]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[25]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[26]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[27]  A. Trautmann,et al.  Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. , 2011, The Journal of investigative dermatology.

[28]  P. Tien,et al.  PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients , 2011, International journal of cancer.

[29]  Yan Zhang,et al.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer , 2010, Cellular and Molecular Immunology.

[30]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[31]  Ian F Tannock,et al.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors , 2010, BMC Cancer.

[32]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[33]  D. Greiner,et al.  Humanized mouse models to study human diseases , 2010, Current opinion in endocrinology, diabetes, and obesity.

[34]  R. Warnke,et al.  PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis , 2010, The American journal of surgical pathology.

[35]  R. Kroczek,et al.  Dendritic Cells Support Homeostatic Expansion of Foxp3+ Regulatory T Cells in Foxp3.LuciDTR Mice , 2010, The Journal of Immunology.

[36]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[37]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[38]  G. Labbadia,et al.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. , 2009, The Journal of clinical investigation.

[39]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[40]  R. Woodland,et al.  A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. , 2008, Clinical immunology.

[41]  H. Spits,et al.  Experimental Models to Study Development and Function of the Human Immune System In Vivo , 2006, The Journal of Immunology.

[42]  S. Rosenberg.  Development of effective immunotherapy for the treatment of patients with cancer. , 2004, Journal of the American College of Surgeons.

[43]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[44]  D. Greiner,et al.  SCID Mouse Models of Human Stem Cell Engraftment , 1998, Stem cells.

[45]  L. Chieco‐Bianchi,et al.  The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. , 1996, Seminars in Immunology.

[46]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[47]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[48]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[49]  G. Ricken,et al.  PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, Clinical neuropathology.

[50]  D. Kurtz,et al.  Tracking cellular and immune therapies in cancer. , 2014, Advances in cancer research.

[51]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[52]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.